News
TERN
5.44
+2.84%
0.15
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. Granted an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer. The equity award was made as a material inducement to Ms. Jung's acceptance of employment with Terns. The company is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates.
Barchart · 20h ago
Amgen stock rallies 13% on GLP-1 weight-loss drug update
Shares of Amgen stock rallies 13% on GLP-1 weight-loss drug update. The biotech giant expressed confidence about its GLp-1 drug candidate MariTide during its Q1 earnings call. Amgen's positive news helped push shares of its potential weight- loss drug rivals lower.
Seeking Alpha · 21h ago
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Terns Pharmaceuticals's (NASDAQ:TERN) cash burn rate is up 37% in the last year. The company burnt through US$67m last year to fund its growth. It has a solid cash runway of 3.9 years from December 2023. Terns pharmaceuticals is an early-stage company and has no debt. We look at the company's cash burn to see how the company is spending its cash.
Simply Wall St · 1d ago
Promising Phase 1 Results for Terns Pharmaceuticals’ TERN-701 Bolster Buy Recommendation
TipRanks · 2d ago
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
Madrigal Pharmaceuticals, Inc. (MDGL) has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH) The drug faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide. The drug is the first to be approved for NASH.
Seeking Alpha · 3d ago
Terns Pharmaceuticals Price Target Maintained With a $5.50/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Benzinga · 3d ago
Terns Pharmaceuticals Price Target Maintained With a $15.00/Share by JMP Securities
Dow Jones · 3d ago
JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $15 Price Target
Benzinga · 3d ago
Evaluating TERN-701’s Potential: A Cautiously Optimistic Hold Rating Pending Efficacy Data
TipRanks · 3d ago
Market Outperform Rating for Terns Pharmaceuticals with a $15 Price Target Based on TERN-701’s Strong Clinical Profile
TipRanks · 4d ago
Terns Pharmaceuticals Reveals Encouraging TERN-701 Study Data
TipRanks · 4d ago
Terns Pharmaceutical releases promising phase 1 data on leukemia candidate
Healthcare Terns Pharmaceutical releases promising phase 1 data on leukemia candidate TERN-701. No significant difference in exposure to the drug based on whether a patient was fasting or not. Company says finding could help differentiate their candidate against others in the BCR-ABL inhibitor class.
Seeking Alpha · 4d ago
BRIEF-Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701
Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701. The drug is being developed by Terns as a potential new treatment for cancer. The company says the study is in the early stages of development.
Reuters · 4d ago
TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND FASTED DOSING
Reuters · 4d ago
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Barchart · 4d ago
Weekly Report: what happened at TERN last week (0422-0426)?
Weekly Report · 5d ago
Optimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and Strategy
TipRanks · 04/26 06:10
Weekly Report: what happened at TERN last week (0415-0419)?
Weekly Report · 04/22 09:18
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
TipRanks · 04/22 06:50
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.